Treasurer of the State of North Carolina grew its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 864,896 shares of the company's stock after buying an additional 27,950 shares during the quarter. Treasurer of the State of North Carolina's holdings in Kenvue were worth $18,466,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also bought and sold shares of the business. Kiley Juergens Wealth Management LLC grew its stake in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after buying an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its position in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after acquiring an additional 500 shares during the period. White Pine Capital LLC raised its stake in shares of Kenvue by 1.0% during the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after acquiring an additional 542 shares during the last quarter. Deseret Mutual Benefit Administrators grew its stake in shares of Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after purchasing an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. increased its holdings in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Trading Up 1.1 %
Shares of KVUE traded up $0.25 during midday trading on Tuesday, hitting $22.96. The stock had a trading volume of 22,262,776 shares, compared to its average volume of 16,951,647. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a market cap of $43.87 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The stock's 50 day moving average is $22.69 and its 200 day moving average is $22.40.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.57%. Kenvue's payout ratio is 154.72%.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on KVUE. Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Redburn Atlantic started coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Finally, Evercore ISI began coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $24.42.
View Our Latest Research Report on KVUE
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
